About Regulating synaptic membrane exocytosis protein 3
Regulating synaptic membrane exocytosis protein 3 (RIMS3) is a protein
from Homo sapiens identified by UniProt accession
Q9UJD0, 308 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Regulating synaptic membrane exocytosis protein 3 |
|---|
| UniProt accession | Q9UJD0 |
|---|
| Gene | RIMS3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 308 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (32)
Diseases linked to this target (Open Targets).
- major depressive disorder · score 0.06
- Autism · score 0.05
- glioblastoma multiforme · score 0.04
- lymphocyte count · score 0.04
- astrocytoma · score 0.04
- atypical teratoid rhabdoid tumor · score 0.03
- central nervous system cancer · score 0.03
- ependymoma · score 0.03
- Chronic Obstructive Asthma · score 0.02
- oligodendroglioma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UJD0-F1 | alphafold | PREDICTED | 71.10 | — |
Amino-acid sequence (308 residues)
MFNGEPGPAS SGASRNVVRS SSISGEICGS QQAGGGAGTT TAKKRRSSLG AKMVAIVGLT QWSKSTLQLP QPEGATKKLR SNIRRSTETG IAVEMRSRVT RQGSRESTDG STNSNSSDGT FIFPTTRLGA ESQFSDFLDG LGPAQIVGRQ TLATPPMGDV HIAIMDRSGQ LEVEVIEARG LTPKPGSKSL PATYIKVYLL ENGACLAKKK TKMTKKTCDP LYQQALLFDE GPQGKVLQVI VWGDYGRMDH KCFMGMAQIM LDELDLSAAV TGWYKLFPTS SVADSTLGSL TRRLSQSSLE SATSPSCS
Explore Regulating synaptic membrane exocytosis protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets